Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.

Antineoplastic Agents / therapeutic use Chemotherapy, Adjuvant / methods Cohort Studies Databases, Factual / statistics & numerical data Disease-Free Survival Humans Japan / epidemiology Kaplan-Meier Estimate Lymphatic Metastasis / therapy Melanoma / diagnosis Neoplasm Recurrence, Local / epidemiology Neoplasm Staging Prognosis Skin Neoplasms / diagnosis
Epidemiology Melanoma

Journal

Journal of dermatological science
ISSN: 1873-569X
Titre abrégé: J Dermatol Sci
Pays: Netherlands
ID NLM: 9011485

Informations de publication

Date de publication:
May 2019
Historique:
received: 28 02 2019
revised: 10 04 2019
accepted: 11 04 2019
pubmed: 27 4 2019
medline: 3 4 2020
entrez: 27 4 2019
Statut: ppublish

Résumé

The American Joint Committee on Cancer (AJCC) 8 The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients. The AJCC 7 In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7 The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7

Sections du résumé

BACKGROUND BACKGROUND
The American Joint Committee on Cancer (AJCC) 8
OBJECTIVE OBJECTIVE
The purpose of this study was to validate the new system using a cohort of Japanese melanoma patients.
METHODS METHODS
The AJCC 7
RESULTS RESULTS
In total, data for 3097 patients were analyzed. The 5-year disease-specific survival according to the 7
CONCLUSION CONCLUSIONS
The results show that new staging system could efficiently classify our Japanese melanoma cohort. Although there was no difference in Stage I and II disease between the 7

Identifiants

DOI: 10.1016/j.jdermsci.2019.04.003 PMID: 31023613
pubmed: 31023613
pii: S0923-1811(19)30096-9
doi: 10.1016/j.jdermsci.2019.04.003
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

284-289

Informations de copyright

Copyright © 2019 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.

Auteurs

Yasuhiro Fujisawa (Y)

Japanese Melanoma Study Group, Japan; Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, University of Tsukuba, Japan. Electronic address: fujisan@md.tsukuba.ac.jp.

Shusuke Yoshikawa (S)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Shizuoka Cancer Center, Japan.

Akane Minagawa (A)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Shinshu University School of Medicine, Japan.

Tatsuya Takenouchi (T)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Niigata Cancer Center, Japan.

Kenji Yokota (K)

Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Nagoya, Japan.

Hiroshi Uchi (H)

Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Kyushu, Japan.

Naoki Noma (N)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Osaka City University, Japan.

Yasuhiro Nakamura (Y)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Saitama Medical University International Medical Center, Japan.

Jun Asai (J)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Kyoto Prefectural University of Medicine, Japan.

Junji Kato (J)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Sapporo Medical University, Japan.

Susumu Fujiwara (S)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Kobe University, Japan.

Satoshi Fukushima (S)

Japanese Melanoma Study Group, Japan; Department of Department of Dermatology and Plastic Surgery, Kumamoto University, Japan.

Jiro Uehara (J)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Asahikawa Medical University, Japan.

Toshihiko Hoashi (T)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Nippon Medical School, Japan.

Tatsuya Kaji (T)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Okayama University Graduate School of Medicine, Japan.

Taku Fujimura (T)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Tohoku University Graduate School of Medicine, Japan.

Kenjiro Namikawa (K)

Japanese Melanoma Study Group, Japan; Department of Dermatologic Oncology, National Cancer Center Hospital, Japan.

Manabu Yoshioka (M)

Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Occupational Environment Health, Japan.

Naoki Murata (N)

Japanese Melanoma Study Group, Japan; Department of Plastic Surgery, University of Hokkaido, Japan.

Dai Ogata (D)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Saitama Medical University, Japan.

Kanako Matsuyama (K)

Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Gifu, Japan.

Naohito Hatta (N)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Toyama Prefectural Central Hospital, Japan.

Yoshitsugu Shibayama (Y)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Fukuoka University, Japan.

Toshiharu Fujiyama (T)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Hamamatsu University School of Medicine, Japan.

Masashi Ishikawa (M)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Saitama Prefectural Cancer Center, Japan.

Daisuke Yamada (D)

Japanese Melanoma Study Group, Japan; Department of Dermatology, University of Tokyo, Japan.

Akiko Kishi (A)

Japanese Melanoma Study Group, Japan; Department of Dermatology, Toranomon Hospital, Japan.

Yoshiyuki Nakamura (Y)

Department of Dermatology, University of Tsukuba, Japan.

Takatoshi Shimiauchi (T)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, Hamamatsu University School of Medicine, Japan.

Kazuyasu Fujii (K)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, Kagoshima University, Japan.

Manabu Fujimoto (M)

Department of Dermatology, University of Tsukuba, Japan.

Hironobu Ihn (H)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Department of Dermatology and Plastic Surgery, Kumamoto University, Japan.

Norito Katoh (N)

Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society, Japan; Department of Dermatology, Kyoto Prefectural University of Medicine, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Classification of 3097 patients from the...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Traitement médicamenteux adjuvant › Classification of 3097 patients from the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Classification of 3097 patients from the...
questionsmedicales.fr › Sciences de l'information › Mémorisation et recherche des informations › Bases de données comme sujet › Bases de données factuelles › Classification of 3097 patients from the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Classification of 3097 patients from the...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Classification of 3097 patients from the...
questionsmedicales.fr › Régions géographiques › Iles › Japon › Classification of 3097 patients from the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › Classification of 3097 patients from the...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Métastase lymphatique › Classification of 3097 patients from the...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › Classification of 3097 patients from the...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Classification of 3097 patients from the...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Classification of 3097 patients from the...
questionsmedicales.fr › Diagnostic › Pronostic › Classification of 3097 patients from the...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › Classification of 3097 patients from the...